REPORT ID 3865

Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Report 2017

Publish Date
14-Dec-17
Pages
107
Format
Electronic (PDF)

In this report, the Asia-Pacific Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Checkpoint Inhibitors for Treating Cancer for these regions, from 2012 to 2022 (forecast), including
    China
    Japan
    South Korea
    Taiwan
    India
    Southeast Asia
    Australia

Asia-Pacific Checkpoint Inhibitors for Treating Cancer market competition by top manufacturers/players, with Checkpoint Inhibitors for Treating Cancer sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Bristol-Myers Squibb(BMS)
    Merck
    Roche
    ...

On the basis of product, this report displays the sales volum, revenue, product price, market share and growth rate of each type, primarily split into
    PD-1 inhibitors
    PD-L1 inhibitors
    CTLA-4 inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Melanoma Treatment
    Bladder Cancer Treatment
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Report 2017
1 Checkpoint Inhibitors for Treating Cancer Overview
    1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer
    1.2 Classification of Checkpoint Inhibitors for Treating Cancer by Product Category
        1.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size (Sales) Comparison by Types (2012-2022)
        1.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 PD-1 inhibitors
        1.2.4 PD-L1 inhibitors
        1.2.5 CTLA-4 inhibitors
    1.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Application/End Users
        1.3.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales (Volume) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Melanoma Treatment
        1.3.3 Bladder Cancer Treatment
        1.3.4 Other
    1.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market by Region
        1.4.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 China Status and Prospect (2012-2022)
        1.4.3 Japan Status and Prospect (2012-2022)
        1.4.4 South Korea Status and Prospect (2012-2022)
        1.4.5 Taiwan Status and Prospect (2012-2022)
        1.4.6 India Status and Prospect (2012-2022)
        1.4.7 Southeast Asia Status and Prospect (2012-2022)
        1.4.8 Australia Status and Prospect (2012-2022)
    1.5 Asia-Pacific Market Size (Value and Volume) of Checkpoint Inhibitors for Treating Cancer (2012-2022)
        1.5.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2022)
        1.5.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2022)

2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Competition by Players/Suppliers, Region, Type and Application
    2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Competition by Players/Suppliers
        2.1.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer (Volume and Value) by Type
        2.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (2012-2017)
        2.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2012-2017)
    2.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer (Volume) by Application
    2.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer (Volume and Value) by Region
        2.4.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Region (2012-2017)
        2.4.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Region (2012-2017)

3 China Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price)
    3.1 China Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        3.1.1 China Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        3.1.2 China Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
        3.1.3 China Checkpoint Inhibitors for Treating Cancer Sales Price Trend (2012-2017)
    3.2 China Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Type
    3.3 China Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Application

4 Japan Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price)
    4.1 Japan Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        4.1.1 Japan Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        4.1.2 Japan Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
        4.1.3 Japan Checkpoint Inhibitors for Treating Cancer Sales Price Trend (2012-2017)
    4.2 Japan Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Type
    4.3 Japan Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Application

5 South Korea Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price)
    5.1 South Korea Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        5.1.1 South Korea Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        5.1.2 South Korea Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
        5.1.3 South Korea Checkpoint Inhibitors for Treating Cancer Sales Price Trend (2012-2017)
    5.2 South Korea Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Type
    5.3 South Korea Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Application

6 Taiwan Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price)
    6.1 Taiwan Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        6.1.1 Taiwan Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        6.1.2 Taiwan Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
        6.1.3 Taiwan Checkpoint Inhibitors for Treating Cancer Sales Price Trend (2012-2017)
    6.2 Taiwan Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Type
    6.3 Taiwan Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Application

7 India Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price)
    7.1 India Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        7.1.1 India Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        7.1.2 India Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
        7.1.3 India Checkpoint Inhibitors for Treating Cancer Sales Price Trend (2012-2017)
    7.2 India Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Type
    7.3 India Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Application

8 Southeast Asia Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price)
    8.1 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        8.1.1 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        8.1.2 Southeast Asia Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
        8.1.3 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Price Trend (2012-2017)
    8.2 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Type
    8.3 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Application

9 Australia Checkpoint Inhibitors for Treating Cancer (Volume, Value and Sales Price)
    9.1 Australia Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)
        9.1.1 Australia Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)
        9.1.2 Australia Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)
        9.1.3 Australia Checkpoint Inhibitors for Treating Cancer Sales Price Trend (2012-2017)
    9.2 Australia Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Type
    9.3 Australia Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share by Application

10 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Players/Suppliers Profiles and Sales Data
    10.1 Bristol-Myers Squibb(BMS)
        10.1.1 Company Basic Information, Manufacturing Base and Competitors
        10.1.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification
            10.1.2.1 Product A
            10.1.2.2 Product B
        10.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
        10.1.4 Main Business/Business Overview
    10.2 Merck
        10.2.1 Company Basic Information, Manufacturing Base and Competitors
        10.2.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification
            10.2.2.1 Product A
            10.2.2.2 Product B
        10.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
        10.2.4 Main Business/Business Overview
    10.3 Roche
        10.3.1 Company Basic Information, Manufacturing Base and Competitors
        10.3.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification
            10.3.2.1 Product A
            10.3.2.2 Product B
        10.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
        10.3.4 Main Business/Business Overview
    ...

11 Checkpoint Inhibitors for Treating Cancer Manufacturing Cost Analysis
    11.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis
        11.1.1 Key Raw Materials
        11.1.2 Price Trend of Key Raw Materials
        11.1.3 Key Suppliers of Raw Materials
        11.1.4 Market Concentration Rate of Raw Materials
    11.2 Proportion of Manufacturing Cost Structure
        11.2.1 Raw Materials
        11.2.2 Labor Cost
        11.2.3 Manufacturing Expenses
    11.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer

12 Industrial Chain, Sourcing Strategy and Downstream Buyers
    12.1 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
    12.2 Upstream Raw Materials Sourcing
    12.3 Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Manufacturers in 2016
    12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders
    13.1 Marketing Channel
        13.1.1 Direct Marketing
        13.1.2 Indirect Marketing
        13.1.3 Marketing Channel Development Trend
    13.2 Market Positioning
        13.2.1 Pricing Strategy
        13.2.2 Brand Strategy
        13.2.3 Target Client
    13.3 Distributors/Traders List

14 Market Effect Factors Analysis
    14.1 Technology Progress/Risk
        14.1.1 Substitutes Threat
        14.1.2 Technology Progress in Related Industry
    14.2 Consumer Needs/Customer Preference Change
    14.3 Economic/Political Environmental Change

15 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Forecast (2017-2022)
    15.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Volume, Revenue and Price Forecast (2017-2022)
        15.1.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate Forecast (2017-2022)
        15.1.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate Forecast (2017-2022)
        15.1.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Price and Trend Forecast (2017-2022)
    15.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate Forecast by Region (2017-2022)
        15.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate Forecast by Region (2017-2022)
        15.2.3 China Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.4 Japan Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.5 South Korea Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.6 Taiwan Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.7 India Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.8 Southeast Asia Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast (2017-2022)
        15.2.9 Australia Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast (2017-2022)
    15.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Price Forecast by Type (2017-2022)
        15.3.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2017-2022)
        15.3.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2017-2022)
        15.3.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Price Forecast by Type (2017-2022)
    15.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2017-2022)

16 Research Findings and Conclusion

17 Appendix
    17.1 Methodology/Research Approach
        17.1.1 Research Programs/Design
        17.1.2 Market Size Estimation
        17.1.3 Market Breakdown and Data Triangulation
    17.2 Data Source
        17.2.1 Secondary Sources
        17.2.2 Primary Sources
    17.3 Disclaimer